Chinese producers may be losing price edge to India, says Granules MD
This article was originally published in Scrip
Chinese firms, stung by increasing costs, are fast losing their price advantage and business, especially in areas like pharmaceutical formulation intermediates (PFIs), has now begun shifting to India, according to Krishna Prasad, managing director of Granules India, an integrated Indian formulations manufacturer.
You may also be interested in...
The termination of the Aurobindo-Sandoz deal isn’t perhaps all bad news for the Indian firm and the flip side may be an improved balance sheet, according to some analysts. But the resolution of compliance issues at manufacturing facilities remains critical.
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.